We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RVLPQ market cap is 99.54. The company's latest EPS is USD -0.5193 and P/E is -2.14.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 263.7M | 240.03M | 177.88M | 79.9M | 49.72M |
| Operating Income | -97.78M | -279.81M | -69.89M | -64.12M | -58.99M |
| Net Income | -109.4M | -270.9M | -79.59M | -64.92M | -51.69M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 795.65M | 463.26M | 370.95M | 144.67M | 128.51M |
| Total Liabilities | 409.38M | 348.55M | 277.09M | 67.94M | 77.42M |
| Total Equity | 386.27M | 114.71M | 93.86M | 76.73M | 51.09M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 37.56M | 33.57M | 17.59M | -54.73M | 44.54M |
| Investing | -4.13M | -4.02M | -3.08M | 116.45M | N/A |
| Financing | 3.61M | -4.69M | 3.68M | -135.33M | N/A |
| Market Cap | 99.54 |
| Price to Earnings Ratio | -2.14 |
| Price to Sales Ratio | 2.22 |
| Price to Cash Ratio | 2.48 |
| Price to Book Ratio | 2.16 |
| Dividend Yield | - |
| Shares Outstanding | 99.54M |
| Average Volume (1 week) | 200 |
| Average Volume (1 Month) | 1.97k |
| 52 Week Change | -99.99% |
| 52 Week High | 0.1115 |
| 52 Week Low | 0.000001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | RVL Pharmaceuticals PLC (CE) |
| Address |
25-28 north wall quay dublin |
| Website | https://www.osmotica.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
